Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 5 Issue 6

Pharmacotherapy of Immunopathological Syndromes Among Patients with Systemic Lupus Erythematosus Based on ABC/VEN Analysis

Ihor Hayduchok*

Lviv Medical Institute, Lviv, Ukraine

*Corresponding Author: Ihor Hayduchok, Lviv Medical Institute, Lviv, Ukraine.

Received: April 07, 2021; Published: May 15, 2021

Abstract

  The article presents the results of the research of pharmacotherapy of immunopathological syndromes among patients with systemic lupus erythematosus based on ABC/VEN analysis. Systemic lupus erythematosus is a systemic autoimmune disease that develops as a result of combined disorders of the immune system that lead to a chronic inflammatory process in many tissues and organs. Comprehensive understanding of immunopathological syndromes among patients with SLE is important for correct diagnosis and proper pharmacotherapy. With the spread of the coronavirus pandemic, the role of pharmacotherapy of immunopathological syndromes among patients with dual health disorders and in patients with systemic diseases becomes very relevant. Pharmacotherapy of immunopathological syndromes among patients with SLE is carried out against the background of basic therapy in accordance with the clinical protocol of medical care on the basis of international and national regulations. Using the ABC/VEN analysis author formed a list of drugs used in pharmacotherapy keeping in mind average cost of treatment.

Keywords: Systemic Lupus Erythematosus; Immunopathological Syndromes; Pharmacotherapy; ABC/VEN Analysis

References

  1. M Cojocaru., et al. “Manifestations of Systemic Lupus Erythematosus”. Maedica (Bucur) 6.4 (2011): 330-336.
  2. “Systemic Lupus Erythematosus (SLE)”. CDC (2021).
  3. Zhi-Chao Yuan., et al. “Gene polymorphisms and serum levels of sVEGFR-1 in patients with systemic lupus erythematosus”. Scientific Report1 (2020): 15-31.
  4. F Rees., et al. “The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies”. Rheumatology (Oxford)11 (2017): 1945-1961.
  5. S Jarukitsopa., et al. “Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States”. Arthritis Care and Research (Hoboken)6 (2015): 817-828.
  6. M Alonso., et al. “Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study”. Medicine (Baltimore)5 (2011): 350-358.
  7. F Rees., et al. “The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012”. Annals of the Rheumatic Diseases 1 (2016): 136-141.
  8. Gronhagen C., et al. “Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden”. The British Journal of Dermatology 6 (2011): 1335-1341.
  9. M Petersen., et al. “Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark”. Lupus9 (2018): 1424-1430.
  10. Kumutnart Chanprapaph., et al. “Dermatologic Manifestations, Histologic Features and Disease Progression among Cutaneous Lupus Erythematosus Subtypes: A Prospective Observational Study in Asians”. Dermatology and Therapy1 (2021): 131-147.
  11. Eui Hyun Oh., et al. “Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea”. Journal of Dermatology4 (2018): 436-443.
  12. Hayduchok IG., et al. “Control regime of antibacterial drugs for pharmacotherapy of coronavirus disease (COVID-19) among patients with dual disorders: an information letter about innovations”. Hayduchok I.G., Shapovalova V.O., Shapovalov V.V., Shapovalov V.V. Research and development: Lviv Medical Institute LLC, KhMAPE of the Ministry of Health of Ukraine, Ukrmedpatentinform of the Ministry of Health of Ukraine. K.: Ukrmedpatentinform of the Ministry of Health of Ukraine 230 (2020): 6.
  13. Hayduchok IG., et al. Control regime of drugs for pharmacotherapy of coronavirus disease (COVID-19) in patients with systemic diseases: an information letter about innovations”. Hayduchok I.G., Shapovalova V.O., Shapovalov V.V., Shapovalov V.V. Research and development: Lviv Medical Institute LLC, KhMAPO of the Ministry of Health of Ukraine, Ukrmedpatentinform of the Ministry of Health of Ukraine. K. Ukrmedpatentinform of the Ministry of Health of Ukraine 25225-2020 (2020): 6.
  14. VO Shapovalova., et al. “Coronavirus disease pandemia 2019: growth of epidemic dangers”. Acta Scientific Pharmaceutical Sciences7 (2020): 61-68.
  15. ATC-classification. [Electronic resource]. Compendium on-line.
  16. On approval of the clinical protocol for providing of medical care to patients with systemic lupus erythematosus [Electronic resource]: Order of the Ministry of Health of Ukraine dated (2006).
  17. National list of basic medicines [Electronic resource]: Resolution of the Cabinet of Ministers of Ukraine of (2009).
  18. On approval of the twelfth issue of the State formulary of medicines and ensuring its availability [Electronic resource]: Order of the Ministry of Health of Ukraine dated (2020).
  19. Shapovalov VV., et al. “Experience of the USA concerning and organization of healthcare system for the pharmaceutical provision for privileged categories of citizens [Electronic resourse]”. Annals of Mechnikov Institute 1 (2019): 81-87.
  20. Shapovalov VV., et al. “Experience of Great Britain in organization of healthcare system for pharmaceutical provision with medicines for privileged categories of citizens”. Health of Society1 (2019): 36-40.
  21. Guideline 00446. Systemic lupus erythematosus. [Electronic resource]: Author: Heikki Julkunen. Original text editor: Anna Kattainen. Date of last update: (2017).
  22. On approval of the List of medicines permitted for use in Ukraine, which are released without prescriptions from pharmacies and their structural units [Electronic resource]: Order of the Ministry of Health of Ukraine dated (2019).
  23. V Shapovalov., et al. “Organizational and legal analysis of the pharmaceutical provision for the most common diseases of society”. International Journal of Pharmaceutical Sciences Review and Research1 (2018): 118-124.
  24. V Shapovalov., et al. “Concerning the importance of forensic and pharmaceutical researches to improve patients’ accessibility to medicines”. Pharmacia 2 (2017): 23-29.
  25. V Shapovalov., et al. “Forensic and pharmaceutical study of the presence of a causal link between the degree of alcohol abuse and qualification level of the respondents”. Pharmacia3 (2017): 31-39.

Citation

Citation: Ihor Hayduchok. “Pharmacotherapy of Immunopathological Syndromes Among Patients with Systemic Lupus Erythematosus Based on ABC/VEN Analysis”.Acta Scientific Medical Sciences 5.6 (2021): 67-73.

Copyright

Copyright: © 2021 Ihor Hayduchok. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor0.851

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US